Browse the evidence

Variant screening of PYY 3–36 led to the development of highly selective long-acting analogs against the Y 2 receptor.

This suggests potential for new treatments targeting the Y 2 receptor in diabetes.

The supramolecular GLP-1 receptor agonist (PA-GLP1) formulation achieved sustained serum concentrations for at least 40 days in a rat model of type 2 diabetes.

This formulation may provide a long-lasting treatment option for diabetes management.

The findings support nephroprotective mechanisms of GLP-1RAs independent of body weight and glycemic control.

This indicates that GLP-1RAs may be beneficial for kidney health beyond their metabolic effects.

BGM1812 was developed through a step-by-step modification process guided by structure-based drug design and molecular dynamics simulations.

Understanding the development process can inform future drug design strategies.

Alternative PET tracers and novel techniques have improved understanding of human BAT physiology.

Emerging imaging techniques can enhance research and clinical understanding of BAT's role in health.

GLP-1 medicines may suppress tumorigenesis through various mechanisms.

Further research is needed to understand the mechanisms by which GLP-1 medicines may affect tumorigenesis.

GPR75 is an attractive pharmacological target for the treatment of obesity and metabolic syndrome.

Targeting GPR75 may lead to more effective treatments for obesity and metabolic syndrome.

Gene targeting of GPR75 is more effective than current pharmacologic therapies without the known side effects.

Gene targeting may provide a safer and more effective alternative to current obesity treatments.

GPR75 and its ligand promote hypertension, inflammation, obesity, and insulin resistance.

Understanding the role of GPR75 can inform strategies to mitigate obesity-related health risks.

Carbon monoxide (CO) has potential therapeutic applications in obesity treatment.

Practitioners might explore CO-based therapies as innovative options for obesity management.

GLP-1 RAs slow both thoracic and abdominal aneurysm growth.

GLP-1 RAs may be beneficial in managing aneurysms in clinical settings.

Resmetirom is the first drug approved for MASLD, demonstrating histological efficacy in addressing both steatohepatitis and fibrosis.

Practitioners can consider resmetirom as a treatment option for MASLD.

The review discusses the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders.

Understanding the role of metabolic drugs in managing inflammatory comorbidities can enhance treatment strategies.

Metabolic drugs may be repurposed as direct anti-inflammatory agents.

Exploring the repurposing of metabolic drugs could lead to new anti-inflammatory therapies.

The optimized nanocomplex of semaglutide with protamine and zinc exhibited a particle size of 196.0 nm and a zeta potential of -45.7 mV.

The nanocomplex's size and charge may influence its delivery and efficacy.

The nanocomplexes showed markedly delayed release of semaglutide, with only 19% drug release over 7 days.

The delayed release may improve the effectiveness of semaglutide in clinical settings.

Key chemobiological mechanisms implicated in obesity include dysregulated leptin-ghrelin signaling, chronic low-grade inflammation, and altered adipokine profiles.

Understanding these mechanisms can help in developing targeted interventions for obesity.

Receptor activity-modifying proteins (RAMPs) are involved in the incidence of obesity and diabetes mellitus.

Understanding the role of RAMPs may help in developing targeted therapies for obesity and diabetes.

Dysregulation of pathways involving class B1 receptors can lead to obesity and diabetes mellitus.

Addressing dysregulation in these pathways may be crucial for obesity and diabetes management.

More research is required to fully understand the contribution of RAMPs to obesity and diabetes.

Future studies should focus on RAMPs to clarify their roles in obesity and diabetes.

Advances in understanding molecular causes of rare genetic obesities have led to therapies targeting appetite regulation.

Practitioners should consider new therapies targeting appetite regulation for patients with rare genetic obesities.

Emerging therapeutic strategies are focusing on novel targets such as growth differentiation factor 15 (GDF15) and bile acid receptors including the farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5).

Practitioners should stay informed about these novel molecular targets for potential future therapies in obesity management.

GLP-1 receptor agonists can exist stably in patients for a long time, overcoming the short half-life of natural GLP-1.

Practitioners can expect longer-lasting effects from GLP-1 receptor agonists compared to natural GLP-1.

The effects of rifampicin on obesity are mediated through Sirt6.

Targeting Sirt6 may enhance the effectiveness of rifampicin in obesity treatment.